The Protocol Review and Monitoring System (PRMS) oversees and ensures the scientific merit, appropriate resourcing and progress of all clinical studies at the University of Kansas Cancer Center (KUCC). The PRMS evaluation process occurs prior to submission to the University of Kansas Medical Center (KUMC) institutional review board (IRB), called the Human Subjects Committee (HSC). The PRMS process is complementary to the HSC review and does not overlap or duplicate the responsibilities of the HSC. The three components of the PRMS are the Disease Working Groups (DWGs;Parvesh Kumar, MD), the Executive Resourcing Committee (ERC;Raymond P. Perez, MD, Chair) and the Protocol Review and Monitoring Committee (PRMC;Stephen K. Williamson, MD, Chair). Although each component has a unique role, combined these are aligned to ensure that research ideas and protocols are efficiently moved through the system, receive high-quality peer-review and monitoring, and that the research portfolio is consistent with KUCC clinical research priorities. The DWGs are charged with initial review of protocol merit and feasibility, and with prioritizing by disease-site and stage. The ERC reviews protocol resource requirements, available funding, fit within the DWG portfolio, and alignment with KUCC research programs and priorities. The PRMC performs independent scientific merit and biostatistical reviews, including rationale, design, statistical analysis plan, and adequacy of the data safety monitoring. In 2010, a total of 89 new protocols were reviewed by the PRMS for merit, and 240 active protocols were monitored for scientific progress. The PRMC also monitors active protocols at least annually for continued scientific merit, clinical appropriateness, progress toward completion of scientific objectives, and accrual status, and terminates studies as appropriate. The PRMS is overseen by Deputy Director, Kapil N. Bhalla, MD and is administratively supported by the KUCC Clinical Trials Management shared resource.

Public Health Relevance

For KUCC cancer clinical research, the PRMS: * Prioritizes competing studies and resources based upon KUCC institutional prioritization plan. * Reviews all proposed cancer related protocols for merit of scientific rationale, accrual goals and ethical appropriateness. * Reviews the statistical analysis plan and appropriateness of trial design. * Reviews the adequacy of the data safety monitoring plan to assure oversight of patient safety * Monitors the accrual and scientific progress of studies

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Kansas
Kansas City
United States
Zip Code
Tomilin, Viktor; Reif, Gail A; Zaika, Oleg et al. (2018) Deficient transient receptor potential vanilloid type 4 function contributes to compromised [Ca2+]i homeostasis in human autosomal-dominant polycystic kidney disease cells. FASEB J 32:4612-4623
Raman, Archana; Parnell, Stephen C; Zhang, Yan et al. (2018) Periostin overexpression in collecting ducts accelerates renal cyst growth and fibrosis in polycystic kidney disease. Am J Physiol Renal Physiol :
Kumar, Dhruv; New, Jacob; Vishwakarma, Vikalp et al. (2018) Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression. Cancer Res 78:3769-3782
Vishwakarma, Vikalp; New, Jacob; Kumar, Dhruv et al. (2018) Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds. Sci Rep 8:12163
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Snyder, Vusala; Reed-Newman, Tamika C; Arnold, Levi et al. (2018) Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Front Oncol 8:203
Chen, Yvonnes; Fowler, Carina H; Papa, Vlad B et al. (2018) Adolescents' behavioral and neural responses to e-cigarette advertising. Addict Biol 23:761-771
Mudaranthakam, Dinesh Pal; Thompson, Jeffrey; Hu, Jinxiang et al. (2018) A Curated Cancer Clinical Outcomes Database (C3OD) for accelerating patient recruitment in cancer clinical trials. JAMIA Open 1:166-171
Ranjan, Atul; Iyer, Swathi V; Ward, Christopher et al. (2018) MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget 9:21429-21443
Brody, Jonathan R; Dixon, Dan A (2018) Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA 9:e1469

Showing the most recent 10 out of 177 publications